Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk's Ozempic, the Danish.
Despite off-label use of naltrexone by some patients with fibromyalgia in clinical practice, data from a randomized trial showed no pain relief advantage with the drug over placebo.
Novo Nordisk has announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France.
The guidelines cover approved and off-label uses of systemic therapies and phototherapy, including new treatments that have become available since the last guidelines were published in 2014.